Allelic polygene diagnosis of reward deficiency syndrome and treatment

• US 6,132,724 A
• Filed: 04/29/1998
• Issued: 10/17/2000
• Est. Priority Date: 04/29/1998
• Status: Expired due to Term

• Current Assignee: City of Hope National Medical Center (City of Hope), Synaptamine, Inc., Board of Regents of the University of Texas System (University of Texas System)
• Original Assignee: City of Hope National Medical Center (City of Hope), Board of Regents of the University of Texas System (University of Texas System)
• Inventors: Blum, Kenneth
• Primary Examiner(s): Witz, Jean C.
• Application Number:
  US09/069,886
• Time in Patent Office: 902 Days
• Field of Search: 514/188, 514/561, 424/195.1
• US Class Current: 424/725
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/195 having an amino group
• CPC Class Codes: A61K 31/35 having six-membered rings with one oxygen as the only ring hetero atom
• CPC Class Codes: A61K 31/44 Non condensed pyridines; Hydrogenated derivatives thereof
• CPC Class Codes: A61K 33/24 Heavy metals; Compounds thereof
• CPC Class Codes: A61K 36/41 Crassulaceae (Stonecrop family)
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Enhancement of attentional processing is attained by administration of an endorphinase inhibitor or enkephalinase inhibitor and optionally, a dopamine precursor, or a serotonin precursor, a GABA precursor, or an endorphin or enkephalinase releaser, or certain herbal compounds including Rhodiola rosea extract (Pharmaline) and/or Huperzine. These components promote restoration of normal neurotransmitter function and the components combined enhance the release of dopamine at the nucleus accumbens and are non-addictive. Use of the dopamine precursors L-phenylalanine, or L-Tyrosine, the enkephalinase inhibitor D-phenylalanine, and/or the serotonin precursor -hydroxytryptophan and a natural acetylcholenesterase inhibitor and chromium salts (i.e. picolinate, nicotinate, etc.) is especially preferred, but not limited to assist in relieving symptoms associated with brain phenylalanine deficiency.

Claims

1. A composition comprising

a) an opiate destruction-inhibiting amount of at least one substance which inhibits the enzymatic destruction of a neuropeptidyl opiate, said substance being selected from the group consisting of amino acids, peptides, and analogues or derivatives of amino acids or peptides;

b) a neurotransmitter synthesis-promoting amount of at least one neurotransmitter precursor selected from the group consisting of the dopamine precursors L-Tyr, L-Phe and L-dopa, the serotonin precursors L-Trp and 5-hydroxytryptophan, and the gamma amino butyric acid (GABA) precursors L-glutamine, L-glutamic acid, and L-glutamate;

c) a trytophan concentration enhancing amount of a mineral compound selected from the group consisting of chromium picolinate and chromium nicotinate; and

d) an amount of at least one substance selected from the group consisting of a Rhodiola extract and huperzine the amounts of said substances, said neurotransmitter precursor, said mineral compound and said Rhodiola extract or huperzine being chosen so that the composition is effective in reducing Attention Deficits disorder with or without hyperactivity.

2. The composition of claim 1 where the huperzine is huperzine A.

3. The composition of claim 1 where the Rhodiola extract is Rhodiola rosea extract.

4. The composition of claim 1 where the Rhodiola extract is salidrosid.

5. The composition of claim 1 where the inhibiting substance is D-Phenylalanine.

6. The composition of claim 1 where the neurotransmitter is a catecholamine.

7. The composition of claim 1 where the precursor is L phenylalanine or L-tyrosine.

8. The composition of claim 1 where the opiate is a peptide.

9. The composition of claim 1 where the opiate is an enkephalin.